Pfizer plans fight to hold share against generic cholesterol drugs

10/17/2005 | NYTimes.com

Insurers and government agencies look forward to billions of dollars in savings when they can move patients from Pfizer's cholesterol drug Lipitor to less expensive generics such as Merck's Zocor and newer generics expected to hit the market. Merck's patent on Zocor expires in June; Pfizer plans to fight the migration to generic versions of Zocor by using its marketing muscle and clinical data showing Lipitor is more effective than the generics.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN